PMID- 12777859
OWN - NLM
STAT- MEDLINE
DCOM- 20030623
LR  - 20061115
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 75
IP  - 10
DP  - 2003 May 27
TI  - Risk of lymphoid neoplasia after cardiothoracic transplantation: the influence of 
      underlying disease and human leukocyte antigen type and matching.
PG  - 1698-703
AB  - BACKGROUND: It has been known for more than 20 years that there is an increased 
      risk of lymphoid neoplasia after cardiothoracic transplantation. Recent studies 
      have demonstrated the importance of primary Epstein-Barr virus (EBV) infection 
      and type of immunosuppressive therapy to the cause of these neoplasms, but the 
      contribution of other factors remains equivocal. METHODS: The authors followed 
      1,562 patients undergoing cardiothoracic transplantation at Harefield Hospital, 
      United Kingdom, and used standard cohort methods of analysis to examine whether 
      posttransplant lymphoma risk was related to the underlying disease requiring 
      transplantation or the human leukocyte antigen (HLA) type and matching. Lymphomas 
      were categorized into EBV-associated lymphoproliferative disease (LPD) and 
      EBV-negative non-Hodgkin's lymphoma (NHL), and the authors carried out separate 
      analyses of these. RESULTS: The authors found no significant association between 
      the underlying disease necessitating transplantation and the risk of lymphoid 
      neoplasia. There was also no evidence of a relation of lymphoma risk with the 
      presence or absence of any particular HLA antigen, although significant 
      protective effects of HLA-B14 and -B57 were found when analyses were conducted 
      without adjustment for multiple testing. Risk of LPD was not associated with 
      degree of HLA mismatching, but there was a significant effect of mismatching on 
      risk of EBV-negative tumors. CONCLUSIONS: The differential effect of HLA 
      mismatching on the risks of LPD and EBV-negative NHL provides further evidence 
      that these two tumors are distinct etiologic entities. The authors' results 
      suggest that the immunologic cause of EBV-negative NHL may be different from that 
      of LPD. Investigation of the relation of risk of EBV-negative NHL to degree of 
      immunosuppression is needed.
FAU - Higgins, Craig D
AU  - Higgins CD
AD  - Section of Epidemiology, Institute of Cancer Research, Brookes Lawley Building, 
      Sutton, Surrey, United Kingdom.
FAU - Swerdlow, Anthony J
AU  - Swerdlow AJ
FAU - Smith, John D
AU  - Smith JD
FAU - Hunt, Beverley J
AU  - Hunt BJ
FAU - Thomas, J Alero
AU  - Thomas JA
FAU - Burke, Margaret M
AU  - Burke MM
FAU - Crawford, Dorothy H
AU  - Crawford DH
FAU - Yacoub, Magdi H
AU  - Yacoub MH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Blood Group Incompatibility/complications
MH  - Cohort Studies
MH  - Epstein-Barr Virus Infections/complications
MH  - Female
MH  - HLA Antigens/analysis
MH  - Heart Transplantation/*adverse effects
MH  - Histocompatibility Testing
MH  - Humans
MH  - Lung Transplantation/*adverse effects
MH  - Lymphoma/*etiology
MH  - Lymphoma, Non-Hodgkin/etiology
MH  - Lymphoproliferative Disorders/etiology/virology
MH  - Male
MH  - Risk Factors
EDAT- 2003/06/05 05:00
MHDA- 2003/06/24 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/06/24 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 10.1097/01.TP.0000062571.56977.26 [doi]
PST - ppublish
SO  - Transplantation. 2003 May 27;75(10):1698-703. doi: 
      10.1097/01.TP.0000062571.56977.26.